{"anticipatedPostingDate":"2026-10","denomUnitsSelected":"Participants","description":"DOCR was defined as the time from the first documentation of sCR or CR that was subsequently confirmed, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \\<=4:1 or \\>=1:2 for κ and λ participants, respectively, after counting \\>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \\<=4:1 or \\>=1:2 for κ and λ participants, respectively, after counting \\>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).","reportingStatus":"NOT_POSTED","timeFrame":"Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)","title":"Duration of Complete Response Rate (DOCR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2","type":"SECONDARY"}